Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U54)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.  

 This FOA solicits U54 applications for the PI-DDN Centers whereas the companion FOA, RFA-CA-19-004, solicits discrete research projects that address relevant research opportunities (e.g., mechanisms of immune evasion, model development, validation of a single target, etc.) through U01 applications.


  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): December 17, 2018

RFA-CA-19-003 Expiration Date December 18, 2018

Agency Website



Amount Description

Application budgets are limited to $1.6 million in direct costs per year, and need to reflect the actual needs of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Funding Type





Medical - Clinical Science
Medical - Translational

External Deadline

December 17, 2018